EGFR and non-small cell lung carcinoma: Our results further showed that P2pal-18S potentiated gefitinib inhibition in phosphorylation of ERK, suggesting that targeting PAR2 may inhibit EGFR transactivation and ERK activation to reverse gefitinib resistance in NSCLC (Figures 3B,C).